5 results on '"Cuthbertson, L"'
Search Results
2. INTRODUCTION
- Author
-
Muscedere, John, Bebenek, Sarah Grace, Stockley, Denise, Kinderman, Laura, Barrie, Carol, Salim, S., Warkentin, L., Gallivan, A., Churchill, T., Baracos, V., Khadaroo, R., McCullough, J., Keller, H., Vesnaver, E., Marcus, H., Lister, T., Nasser, R., Belley, L., Laur, C., Gainer, R., Moorhouse, P., Mallery, L., Hirsch, G., Hamilton, G., Wheeler, K., Di Michelle, J., Lalu, M.M, McIsaac, D. I, Mallery, K., Theou, O., Goldstein, J., Armstrong, J., Webb, J., Greene, J., Doyle, E., Douglas, B., Lee, J., Rockwood, K., Whitty, R., Koo, E., Porter, S., Battu, K., Kalocsai, C., Reid, J., Kho, M., Molloy, A., Herridge, M. S, Karachi, T., Fox-Robichaud, A., Koo, K. KY, Lo, V., Mathur, S., McCaughan, M., Pellizzari, J., Rudkowski, J., Figueiredo, S., Morais, J., Mayo, N., Meffen, K., Penner, C., Meyyappan, R., Sandoval, R., Broderick, J., Hoffer, A., Chambers, S., Ball, I., Martin, C., Awan, S., Rajji, T., Uranis, C., Kim, D., Burhan, A., Ting, R., Ito, H., Graff, A., Gerretsen, P., Woo, V., Mulsant, B., Davies, S., Paul, L. Read, Spice, R., Sinnarajah, A., Ho, G., Webb, M., Uniacke, J., Linsey, J., Kettle, J., Salmon, C., Mohammed, R., Whitby, C., Cowie, B., Wang, S., Sawatzky, R., Chan, E., Wolfs, D., Harding, W., Laforest, E., Schick-Makaroff, K., King, G., Cohen, S. R., Neufeld, C., Lett, J., Voth, J., Durepos, P., Wickson-Griffiths, A., Hazzan, A. Abiola, Kaasalainen, S., Vastis, V., Battistella, L., Papaioannou, A., Asselin, G., Klein, D., Tan, A., Kendell, C., Burge, F., Kotecha, J., Marshall, E., Cash, C., Tschupruk, C., Urquhart, R., Cottrell, L., Erbacker, L., Pesut, B., Duggleby, W., Bui, M., Te, A., Brazil, E., Sussman, T., Team, SPA-LTC, Delicaet, K., MacDonald, J., Hartwick, M., des Ordons, A. Roze, Myers, J., Pereira, J., Simon, J., Abdul-Razzak, A., Sharma, A., Ogilvie, L., Downar, J., Choukou, M.A., Holroyd-Leduc, J. M., Kazanjian, A., Durand, P. J, Straus, S. E, Légaré, F., Turgeon, A. F., Tourigny, A., Dumont, S., Mc Giguere, A., Lounsbury, K., Friesen, D., Bitschy, A., Donald, E. E, Stajduhar, K., Knapp, A., Klinger, C., Wentlandt, K., Urowitz, S., Walton, T., Chahal, M., Zwicker, V., Cohen, T., Morales, M. López, Miller, K., Duggan, K., Barnett-Cowan, M., Kortes-Miller, K., Kelley, M. Lou, Nayfeh, A., Marcoux, I., Jutai, J., Virag, O., Khakoo, A., Incardona, N., Workentin, K., Maxwell, C., Stock, K., Hogan, D. B., Tyas, S. L., Bronskill, S. E., Morris, A. M., Bell, C. M., Jeffs, L., Gandhi, S., Blain, J., Toubasi, S., Andrew, M., Ashe, M., Atkinson, E., Ayala, A. P., Bergman, H., Ploeg, J., McGilton, K., Patten, S. B., Maxwell, C. J., Delleman, B., Chan, D., Siu, H., Howard, M., Mangin, D., Akioyamen, L., Hoben, M., Estabrooks, C., McArthur, C., Gibbs, J. C., Patel, R., Neves, P., Killingbeck, J., Hirdes, J., Milligan, J., Berg, K., Giangreogrio, L., Adekpedjou, R., Stacey, D., Brière, N., Freitas, A., Marjolein, M., Garvelink, Turcotte, S., Heyer, M., Boscart, V., Heckman, G., Zahradnik, M., Jeffs, L. P., Mainville, C., Maione, M., Morris, A., Bell, C., Bronskill, S., Tscheng, D., Sever, L., Hyland, S., Emond, J., Garvelink, M., Menear, M., MacLeod, T., LeBlanc, C., Allen, M., McLean-Veysey, P., Rodney-Cail, N., Steeves, B., Bezanson, E., Van Ooteghem, K., Trinh, A., Cowan, D., Kwok, L., Fels, D., Meza, M., Fels-Leung, S., Ouellette-Kuntz, H., McKenzie, K., Martin, L., Bark, D., Hanafi, S., Gibson, W., Wagg, A., Tanel, M., Laing, A., Weaver, T., Lupo, J., Giangregorio, L., Payne, A., Sheets, D., Beach, C., Elliott, J., Stolee, P., Stinchcombe, A., Bédard, M., Enright, J., Wilson, K., Ozen, L., Silman, J., Gibbons, C., McKinnon, T., Timble, J., Willison, K., Boland, L., Perez, M. Margarita Becerra, McIsaac, D., Edmond, J., Brown, K., Leigh, J. Parsons, Buchner, D., Stelfox, H. T., Aziz, J., Crake, D., Ren, Z., Grant, T., Goubran, R., Knoefel, F., Sveistrup, H., Bilodeau, M., Oliver, J., Chidwick, P., Booi, L., Magyar, T., Martin, M., Ko, J. Hyun, Shannon, J., Wilson-Pease, E., Kephart, G., Babin, N., Malik, H., Maximos, M., Seng, S., Vandenberg, G., Dal Bello-Haas, V., Lagrotteria, A., Sullivan, K., Mihaylova, A., Lu, C., Koh, J., Hamielec, C., Steer, M., Jimenez, C., Woo, K., Julian, P., Martin, L. Schindel, McLelland, V., Ryan, D., Wilding, L., Chang, C. E., van Schooten, K. S, Wong, F., Robinovitch, S. N, Balasubramanaiam, B., Chenkin, J., Snider, T. G., Melady, D., Lee, J. S., Petrella, A., Heath, M., Shellington, E., Laguë, A., Voyer, P., Ouellet, M., Boucher, V., Pelletier, M., Gouin, É., Daoust, R., Berthelot, S., Giroux, M., Sirois, M., Émond, M., Bergstrom, V., Tate, K., Lee, S., Reid, C., Rowe, B., Cummings, G., Holroyd-Leduc, J., El-Bialy, R., Zhao, B., Baumbusch, J., Busson, C., Kohr, R., Donovan, J., Philpott, K., Kingston, J., Rickards, T., Weiler, C., Lanovaz, J., Arnold, C., Chiu, K., Cuperfain, A., Zhu, K., Zhao, X., Zhao, S., Iaboni, A., Perrella, A., Chau, V., Hu, C. Dong, Farooqi, M., Patel, S., Bauer, J., Lee, L., Schill, C., Patel, T., Mroz, L., Kryworuchko, J., Carter, R., Spencer, L., Barwich, D., Roy, N., Després, C., Leyenaar, M., McLeod, B., Poss, J., Costa, A., Blums, J., Costa, I. Geraldina, Tregunno, D., Kirkham, J., Seitz, D., Velkers, C., Krawczyk, M., Garland, E., Michaud, M., Pakzad, S., Bourque, P. E., Eamer, G., Gibson, J. A, Gillis, C., Hsu, A. T, MacDonald, E., Whitlock, R., Khadaroo, R. G, Brisebois, R., Clement, F., Hathaway, J., Bagheri, Z. S., Costa, I. G., Schinkel-Ivy, A., Rodney, P. (Paddy), Varcoe, C., Jiwani, B., Fenton, T., Gramlich, L., Tangri, N., Eng, F., Bohm, C., Komenda, P., Rigatto, C., Brar, R., McCloskey, R., Keeping-Burke, L., Donovan, C., Verma, A., Razak, F., Kwan, J., Lapointe-Shaw, L., Rawal, S., Tang, T., Weinerman, A., Guo, Y., Mamdani, M., McNicholl, T., Valaitis, R., Tarraf, R., Boakye, O., Suter, E., Boulanger, P., Birney, A., Sadowski, C. A, Gill, G., Mrklas, K., Plaisance, A., Noiseux, F., Francois, R., LeBlanc, A., McGinn, C. A., Tapp, D., Archambault, P. M., Begum, J., Wikjord, N., Roy, P., Reimer-Kirkham, S., Doane, G., Hilliard, N., Giesbrech, M., Dujela, C., Harerimana, B., Forchuk, C., Booth, R., Vasudev, A., Isaranuwatchai, W., Seth, P., Ramsey, D., Rudnick, A., Heisel, M., Reiss, J., Lee, E., Mate, K., Aubertin-Leheude, M., Fiore, J., Auais, M., Moriello, C., Scott, S., Wilson, M., McDonald, E., Lee, T., Arora, N., Hanvey, L., Elston, D., Heyland, R., Heyland, D., Langevin, J., Fang, Q., Price, D., Nowak, C., Fang, H., Richardson, J., Phillips, S., Gordon, C., Xie, F., Adachi, J., Tang, A., Swinton, M., Winhall, M., Clark, B., Sinuff, T., Abelson, J., You, J., Shears, M., Takaoka, A., Tina, M., Amanda, H., Surenthar, T., Li, G., Rochwerg, B., Woo, T., Bagshaw, S., Johnstone, J., Cook, D., Beaton, D., Drance, E., Leblanc, M.E., O’Connor, D., Ono, E., Phinney, A., Reid, R. C., Rodney, P. A., Tait, J., Ward-Griffin, C., Millen, T., Clarke, F., Thabane, L., Dogba, M. J., Rivest, L.l, Durand, P. J., Fraser, K., Bourassa, H., Embuldeniya, G., Farmanova, E., Auguste, D., Witteman, H. O, Kröger, E., Beaulieu, É., MC Giguere, A., Paragg, J., Swindle, J., Webber, T., Porterfield, P., Husband, A., Kryworucko, J., Trenaman, L., Bryan, S., Cuthbertson, L., Bansback, N., de Grood, C., Dodek, P., Fowler, R., Forster, A., Boyd, J., Stelfox, H., Kruger, S., Steinberg, M., Quinn, K., Yarnell, C., Fu, L., Manuel, D., Tanuseputro, P., Stukel, T., Pinto, R., Scales, D., Laupacis, A., Varughese, R., Huang, A., Famure, O., Chowdhury, N., Renner, E., Kim, J., MacIver, J., Singer, L., Gali, B., Brewster, P., Asche, C., Mitz, A., Hundza, S., MacDonald, S., Kaechele, N., Donald, E., Kaur, S., Fernandes, P., Pauloff, K., Gordon, A., Kallan, L., Grinman, M., Human, T., Ying, I., Pattullo, A., Wong, H., Feldman, S., Moffat, D., Zjadewicz, K., McIntosh, C. J., Alghamdi, M., McComb, A., Ferrone, A., Geng, W., Weeks-Levy, C., and Menon, C.
- Subjects
Abstracts ,Canadian Frailty Network Abstracts from the Meeting in Toronto, September 27–29, 2015 ,Canadian Frailty Network Abstracts from the Meeting Held in Toronto, April 23–24, 2017 - Published
- 2017
3. Metformin in adults with type 1 diabetes
- Author
-
Petrie, John R., Chaturvedi, Nish, Ford, Ian, Hramiak, Irene, Hughes, Alun D., Jenkins, Alicia J., E. Klein, Barbara, Klein, Ron, Ooi, Teik Chye, Rossing, Peter, Sattar, Naveed, Stehouwer, Coen D. A., Colhoun, Helen M., Ford, I, Kean, S, Thomson, E, Gillespie, L, Gibb, J, Greenlaw, N, Hramiak, I, Keech, A, Jenkins, A, Chaturvedi, N, Hughes, A, March, K, Coady, E, Tillin, T, Bots, M, Klein, R, Klein, B, Dreyer, J, Jan, T, Meuer, S, Murach, D, Sheffy, Koby, Lusky, Ravit, Peleg, S, Petrie, J, Colhoun, H, Shore, A, Carty, D, Donnan, P, Witham, M, Adler, A, Lonn, E, Rauchhaus, P, Lindsay, R, Brouwers, M, Van‐Melckebeke, J, Hamill, T, Cuthbertson, L, Murray, A, Jolly, L, Miller, E, Sattar, N, Hair, J, Bell, A, Carmichael, S, Douglas, E, Surtees, P, Dinnett, E, Allan, J, Watson, C, McLaughlin, M, Brindley, G, Smillie, E, Motherwell, D, MacDonald, S, Ellis, P, Stuart, D, Travers, M, Brearley, S, Greig, L, Haw, J, MUMC+: HVC Pieken Maastricht Studie (9), MUMC+: MA Interne Geneeskunde (3), RS: CARIM - R3.01 - Vascular complications of diabetes and the metabolic syndrome, and Interne Geneeskunde
- Subjects
Blood Glucose ,Male ,Glycated Hemoglobin A ,endocrine system diseases ,type 1 diabetes ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Placebo-controlled study ,PROGRESSION ,030204 cardiovascular system & hematology ,PLACEBO-CONTROLLED TRIAL ,Carotid Intima-Media Thickness ,INTIMA-MEDIA THICKNESS ,Glycated Hemoglobin A/drug effects ,hypoglycaemia metformin ,DISEASE ,law.invention ,0302 clinical medicine ,Endocrinology ,Metformin/administration & dosage ,Randomized controlled trial ,Clinical Protocols ,endothelial function ,law ,Risk Factors ,GLYCEMIC CONTROL ,Clinical endpoint ,Insulin ,Single-Blind Method ,Non-U.S. Gov't ,Research Support, Non-U.S. Gov't ,cardiovascular ,Diabetes ,ACTIVATED PROTEIN-KINASE ,Cardiovascular disease (CVD) ,clinical trial ,ASSOCIATION ,Middle Aged ,Metformin ,Multicenter Study ,VITAMIN-B-12 DEFICIENCY ,Cholesterol ,Cholesterol, LDL/blood ,Combination ,Randomized Controlled Trial ,POTENTIAL ROLE ,Disease Progression ,Original Article ,Drug Therapy, Combination ,Female ,medicine.drug ,Type 1 ,Adult ,medicine.medical_specialty ,complications ,METFORMIN ,030209 endocrinology & metabolism ,Hypoglycemia/chemically induced ,METABOLISM ,Placebo ,Research Support ,LDL ,03 medical and health sciences ,Blood Glucose/drug effects ,Drug Therapy ,Double-Blind Method ,Internal medicine ,Internal Medicine ,medicine ,Diabetes Mellitus ,Journal Article ,Hypoglycemic Agents ,Humans ,carotid intima media thickness ,Body Weight/drug effects ,adjunct therapy ,Glycated Hemoglobin ,Type 1 diabetes ,business.industry ,Body Weight ,nutritional and metabolic diseases ,Atherosclerosis/drug therapy ,Diabetes Mellitus, Type 1/blood ,weight ,Original Articles ,Cholesterol, LDL ,medicine.disease ,Atherosclerosis ,Hypoglycemic Agents/administration & dosage ,Hypoglycemia ,Surgery ,Clinical trial ,Diabetes Mellitus, Type 1 ,business ,Insulin/administration & dosage - Abstract
Aims: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes (T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no data on its cardiovascular effects. We have therefore initiated an international double-blind, randomized, placebo-controlled trial (REMOVAL: REducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes) to examine whether metformin reduces progression of atherosclerosis in adults with T1D. Individuals >= 40 years of age with T1D for >= 5 years are eligible if they have >= 3 of 10 specified CV risk factors. The enrolment target is 500 participants in 17 international centres.Materials and methods: After 12 weeks of single-blind placebo-controlled run-in, participants with >= 70% adherence are randomized to metformin or matching placebo for 3 years with insulin titrated towards HbA1c 7.0% (53 mmol/mol). The primary endpoint is progression of averaged mean far wall common carotid intima-media thickness (cIMT) measured by ultrasonography at baseline, 12, 24 and 36 months. This design provides 90% power to detect a mean difference of 0.0167 mm in cIMT progression between treatment arms (alpha = 0.05), assuming that up to 20% withdraw or discontinue treatment. Other endpoints include HbA1c, weight, LDL cholesterol, insulin requirement, progression of retinopathy, endothelial function and frequency of hypoglycaemia.Conclusion: REMOVAL is the largest clinical trial of adjunct metformin therapy in T1D to date and will provide clinically meaningful information on its potential to impact CV disease and other complications.
- Published
- 2017
- Full Text
- View/download PDF
4. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL) : a double-blind, randomised, placebo-controlled trial
- Author
-
Petrie, John R., Chaturvedi, Nishi, Ford, Ian, Brouwers, Martijn C. G. J., Greenlaw, Nicola, Tillin, Therese, Hramiak, Irene, Hughes, Alun D., Jenkins, Alicia J., Klein, Barbara E K, Klein, Ronald, Ooi, Teik C., Rossing, Peter, Stehouwer, Coen D. A., Sattar, Naveed, Colhoun, Helen M., Nickerson, H., Lou, O., Dutta, S., Haw, J., Anderson, C., Kean, S., Thomson, E., Gillespie, L., Gibb, J., Greenlaw, N., Keech, Anthony C., Jenkins, Mark A., March, K., Williams, S., Coady, E., Bots, M., Dreyer, J., Jan, T., Sheffy, K., Lusky, R., Peleg, S., Shore, A., Carty, D., Donnan, P., Witham, M., Adler, A.., Lonn, E, Rauchhaus, P., Lindsay, R.W., Brouwers, M., Van-Melckebeke, J., Hamill, T., Cuthbertson, L., and REMOVAL Study Group
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Internal Medicine - Abstract
Background Metformin might reduce insulin requirement and improve glycaemia in patients with type 1 diabetes, but whether it has cardiovascular benefits is unknown. We aimed to investigate whether metformin treatment (added to titrated insulin therapy) reduced atherosclerosis, as measured by progression of common carotid artery intima-media thickness (cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease. Methods REMOVAL was a double-blind, placebo-controlled trial undertaken at 23 hospital diabetes clinics in five countries (Australia, Canada, Denmark, the Netherlands, and the UK). Adults aged 40 years and older with type 1 diabetes of at least 5 years' duration and at least three of ten specific cardiovascular risk factors were randomly assigned (via an interactive voice response system) to oral metformin 1000 mg twice daily or placebo. Participants and site staff were masked to treatment allocation. The primary outcome was averaged mean far-wall cIMT, quantified annually for 3 years, analysed in a modified intention-to-treat population (all randomly assigned participants with post-randomisation data available for the outcome of interest at any given timepoint, irrespective of subsequent adherence or study participation), using repeated measures regression. Secondary outcomes were HbA1c, LDL cholesterol, estimated glomerular filtration rate (eGFR), incident microalbuminuria (not reported), incident retinopathy, bodyweight, insulin dose, and endothelial function, also analysed in all participants with post-randomisation data available for the outcome of interest at any given timepoint. This trial is registered with ClinicalTrials.gov, number NCT01483560. Findings Between Dec 14, 2011, and June 24, 2014, 493 participants entered a 3 month run-in to optimise risk factor and glycaemic control (single-blind placebo in the final month). Of 428 randomly assigned patients, 219 were allocated to metformin and 209 to placebo. Progression of mean cIMT was not significantly reduced with metformin (−0·005 mm per year, 95% CI −0·012 to 0·002; p=0·1664), although maximal cIMT (a prespecified tertiary outcome) was significantly reduced (−0·013 mm per year, −0·024 to −0·003; p=0·0093). HbA1c (mean 8·1% [SD 0·9] for metformin and 8·0% [0·8] for placebo at baseline) was reduced on average over 3 years by metformin (−0·13%, 95% CI −0·22 to −0·037; p=0·0060), but this was accounted for by a reduction at the 3-month timepoint (−0·24%, −0·34 to −0·13; p
- Published
- 2017
5. Rearing and foraging affects bumblebee (Bombus terrestris) gut microbiota
- Author
-
Newbold, LK, Oliver, AE, Cuthbertson, L, Walkington, SE, Gweon, HS, Heard, MS, and Van der Gast, CJ
- Subjects
Biology and Microbiology ,Agriculture and Soil Science ,Ecology and Environment - Abstract
© 2015 Society for Applied Microbiology and John Wiley & Sons Ltd. Bumblebees are ecologically and economically important as pollinators of crop and wild plants, especially in temperate systems. Species, such as the buff-tailed bumblebee (Bombus terrestris), are reared commercially to pollinate high-value crops. Their highly specific gut microbiota, characterized by low diversity, may affect nutrition and immunity and are likely to be important for fitness and colony health. However, little is known about how environmental factors affect bacterial community structure. We analysed the gut microbiota from three groups of worker bumblebees (B.terrestris) from distinct colonies that varied in rearing and foraging characteristics: commercially reared with restricted foraging (RR); commercially reared with outside foraging (RF); and wild-caught workers (W). Contrary to previous studies, which indicate that bacterial communities are highly conserved across workers, we found that RF individuals had an intermediate community structure compared with RR and W types. Further, this was shaped by differences in the abundances of common operational taxonomic units (OTUs) and the diversity of rare OTUs present, which we propose results from an increase in the variety of carbohydrates obtained through foraging.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.